<DOC>
	<DOCNO>NCT00213590</DOCNO>
	<brief_summary>The purpose study show efficacy reduction cyclosporine A exposure measure area curve Bayesian estimator primary prevention degradation renal function renal transplant recipient</brief_summary>
	<brief_title>Renal Function Evaluation After Reduction Cyclosporine A Dose Renal Transplant Patients</brief_title>
	<detailed_description>Study population Eligible patient 18 75 year age primary secondary renal transplant recipient second year posttransplant stable serum creatinine level ( i.e. , &lt; 20 % variation previous 3 month ) . All patient must receive induction therapy , corticosteroid-free least 3 month , receive combination maintenance therapy consist cyclosporine ( trough level , 125 175 ng/mL ) mycophenolate mofetil ( CellCept , F. Hoffmann- La Roche AG , Basel , Switzerland ) 2 g daily . Patients either low high risk graft dysfunction ineligible ; majority participate center maintain low immunological risk patient cyclosporine alone high risk graft dysfunction usually maintain corticosteroid . For study , low risk define presence following : zero one acute rejection episode return renal function previous level corticosteroid treatment , panel-reactive antibody titer &lt; 25 % , serum creatinine level &lt; 125 µmol/L , age &gt; 25 year , donor age &lt; 40 year . High risk define presence least one following : serum creatinine level &gt; 250 µmol/L , proteinuria &gt; 1 g/day , panel-reactive antibody titer &gt; 80 % , &gt; 1 episode T-cell-mediated rejection least one episode antibody-mediated rejection posttransplant , presence vasculitis systemic lupus erythematosus usually treat corticosteroid . Other exclusion criterion evidence systemic infection malignancy within previous 5 year ( except adequately treat nonmetastatic basal squamous cell carcinoma skin ) , leukocyte count &lt; 2.5x103/µL , hemoglobin &lt; 80 g/dL , platelet count &lt; 100x103/µL , severe intestinal disorder , pregnancy , breast feeding , current immunosuppressive treatment drug cyclosporine mycophenolate mofetil . Women childbearing age require use adequate contraception treatment mycophenolate mofetil six week discontinuation . Study Endpoints The primary endpoint proportion patient treatment failure ( failure prevent kidney dysfunction ) 24 month , composite graft loss , histologically confirm acute rejection cyclosporine toxicity , &gt; 15 % increase mean serum creatinine level baseline assessment . The mean current two previous serum creatinine level use determine level baseline , level nadir ( time low serum creatinine measurement ) , level 2 year . The secondary endpoint include change estimate glomerular filtration rate ( eGFR ) baseline calculate use four-variable equation Modification Diet Renal Disease ( MDRD ) Study ; blood pressure , urinary protein , lipid level ; severe adverse event infection require hospitalization , neoplasia , lymphoma ; graft patient survival . Study Follow-up Procedures Weight , blood pressure 10-minute rest , serum creatinine glucose level , complete blood cell count , urinary protein level measure , use immunosuppressive , antihypertensive , lipid-lowering drug record baseline every 2 month . Serum lipid level measure baseline every 6 month . Gynecologic dermatologic examination perform baseline yearly . Adverse event record . Renal biopsy perform creatinine level increase &gt; 20 % relative nadir proteinuria &gt; 1 g/day . The nadir level use reference point obviate risk miss diagnosis rejection low-exposure arm ; serum creatinine level usually fell initiation low exposure regimen . Biopsies classify use Banff 1997 criterion four senior pathologist blind clinical information . CNI-associated nephrotoxicity grade mild , moderate , severe accord Banff 1997 chronicity rejection score .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>first second renal graft cadaveric renal graft second year renal transplantation stable renal function moderate renal dysfunction risk bitherapy cyclosporine A mycophenolate mofetil corticosteroid withdrawal since 3 month le 2 acute rejection episode PRA &gt; 80 % serum creatinine &gt; 250µmol/L 24hour proteinuria &gt; 1g humoral rejection vasculitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>